Mineralcorticoid receptor blockers in chronic kidney disease
There are many experimental data supporting the involvement of aldosterone and mineralcorticoid receptor (MR) activation in the genesis and progression of chronic kidney disease (CKD) and cardiovascular damage.Many studies have shown that in diabetic and non-diabetic CKD, blocking the renin-angioten...
Main Authors: | Sara Erraez, Manuel López-Mesa, Pablo Gómez-Fernández |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-05-01
|
Series: | Nefrología (English Edition) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2013251421000675 |
Similar Items
-
Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
by: Usama Abdel Azim Sharaf El Din, et al.
Published: (2022-07-01) -
Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
by: Usama Abdel Azim Sharaf El Din, et al.
Published: (2022-07-01) -
Consenso de la Sociedad Latinoamericana de Nefrología e Hipertensión en relación con el papel de los antagonistas del receptor mineralocorticoide en enfermedad renal crónica
by: Jorge Rico-Fontalvo, et al.
Published: (2022-04-01) -
Características clínicas de los pacientes diabéticos que acuden por primera vez a una consulta nefrológica en hospitales públicos de Lima
by: Percy Herrera Añazco, et al.
Published: (2014-01-01) -
Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease
by: Jose Luis Górriz, et al.
Published: (2023-07-01)